EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease

Sven Schneider iD, Katharina Poglitsch, Christina Morgenstern, Tamara Quint, Katharina Gangl, Christoph Sinz, Tina Bartosik, Nicholas James Campion, David Tianxiang Liu, Lukas David Landegger iD, Aldine Tu, Victoria Stanek und 3 weitere

European Respiratory Journal · 2023

DOI: 10.1183/13993003.01335-2022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Respiratory Journal, 2023. Verfasst von Sven Schneider und 14 weiteren Autor:innen. Beteiligte Einrichtung: Dept of Otorhinolaryngology, General Hospital and Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Nasal Polyps, Respiration Disorders, Asthma, Rhinitis. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) comprises the triad of chronic rhinosinusitis with nasal polyps, asthma and intolerance to NSAIDs. Dupilumab treatment, targeting the interleukin-4 (IL-4) receptor α, significantly reduces polyp burden as well as asthma symptoms. Here we aimed to investigate the effect of dupilumab on aspirin intolerance, burden of disease and nasal cytokine profiles in patients with N-ERD.

Methods

In this open-label trial, adult patients with confirmed N-ERD were treated with dupilumab for 6 months. Clinical parameters ( e.g. total polyp scores, quality of life questionnaires, smell test, spirometry), oral aspirin provocation testing and blood, nasal and urine sampling were monitored at regular intervals for up to 6 months after starting dupilumab therapy.

Results

Of the 31 patients included in the study, 30 completed both aspirin provocation tests. After 6 months of treatment with dupilumab, 23% of patients (n=7 of 30) developed complete aspirin tolerance and an additional 33% of patients (n=10 of 30) tolerated higher doses. Polyp burden was significantly reduced (total polyp score: −2.68±1.84, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasal PolypsRespiration DisordersAsthmaRhinitisAdultHumansAspirinQuality of LifeAnti-Inflammatory Agents, Non-SteroidalChronic DiseaseAntibodies, Monoclonal, Humanized

Substanzen

AspirinAnti-Inflammatory Agents, Non-SteroidaldupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Dept of Otorhinolaryngology, General Hospital and Medical University of Vienna, Vienna, Austria.
  • Dept of Dermatology, General Hospital and Medical University of Vienna, Vienna, Austria.
  • Science Impuls, Seeboden, Austria.
  • Dept of Dermatology, General Hospital and Medical University of Vienna, Vienna, Austria christine.bangert@meduniwien.ac.at.

ORCID-Profile: Sven Schneider, Lukas David Landegger, Christine Bangert

Förderung

  • AstraZeneca

Zitieren

APA

Schneider, S., Poglitsch, K., Morgenstern, C., Quint, T., Gangl, K., Sinz, C., Bartosik, T., Campion, N. J., Liu, D. T., Landegger, L. D., Tu, A., Stanek, V., Rocha-Hasler, M., Bangert, C., & Eckl-Dorna, J. (2023). Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease. European Respiratory Journal. https://doi.org/10.1183/13993003.01335-2022

Vancouver

Schneider S, Poglitsch K, Morgenstern C, Quint T, Gangl K, Sinz C, et al. Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease. European Respiratory Journal. 2023. doi:10.1183/13993003.01335-2022

BibTeX
@article{Schneider2023,
  author = {Schneider, Sven and Poglitsch, Katharina and Morgenstern, Christina and Quint, Tamara and Gangl, Katharina and Sinz, Christoph and Bartosik, Tina and Campion, Nicholas James and Liu, David Tianxiang and Landegger, Lukas David and Tu, Aldine and Stanek, Victoria and Rocha-Hasler, Marianne and Bangert, Christine and Eckl-Dorna, Julia},
  title = {Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease},
  journal = {European Respiratory Journal},
  year = {2023},
  doi = {10.1183/13993003.01335-2022}
}
Kostenlos starten →